EUVIMEDEUVIMED entdecken
Open Access

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Jiawen Li, Guidong Gong, Yue Zhang, Yanjiang Zheng, Yunxiang He, Mei Chen, Xianglian He, Xiaolan Zheng, Xue Gong, Lei Liu, Kaiyu Zhou, Zongmin Zhao und 4 weitere

Advanced Healthcare Materials · 2025-01 · 14 (2)

DOI: 10.1002/adhm.202403595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 11.11.2024. Verfasst von Jiawen Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, Department of Pediatric Dentistry, West China Second University Ho…. Hauptthemen laut MEDLINE: Polyphenols, Monocytes, Myocardial Infarction, Immunomodulation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Technology Project of Sichuan Province of China, State Key Laboratory of Polymer Materials Engineering, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial infarction is one of the leading cause of cardiovascular death worldwide. Invasive interventional procedures and medications are applied to attenuate the attacks associated with ischemic heart disease by reestablishing blood flow and restoring oxygen supply. However, the overactivation of inflammatory responses and unsatisfactory drug delivery efficiency in the infarcted regions prohibit functional improvement. Here, a nanoengineered monocyte (MO)‐based biohybrid system, referred to as CTAs @MOs, for the heart‐targeted delivery of combinational therapeutic agents (CTAs) containing anti‐inflammatory IL‐10 and cardiomyogenic miR‐19a to overcome the limitation of malperfusion within the infarcted myocardium through a polyphenol‐mediated interfacial assembly, is reported. Systemic administration of CTAs@MOs bypasses extensive thoracotomy and intramyocardial administration risks, leading to infarcted heart‐specific accumulation and sustained release of therapeutic agents, enabling immunomodulation of the proinflammatory microenvironment and promoting cardiomyocyte proliferation in sequence. Moreover, CTAs@MOs, which serve as a cellular biohybrid‐based therapy, significantly improve cardiac function as evidenced by enhanced ejection fractions, increased fractional shortening, and diminished infarct sizes. This polyphenol nanoengineered biohybrid system represents a general and potent platform for the efficient treatment of cardiovascular disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolyphenolsMonocytesMyocardial InfarctionImmunomodulationAnimalsMicroRNAsInterleukin-10HumansMaleMiceMyocytes, CardiacRats

Stichwörter der Autor:innen

biohybriddrug deliveryimmunologymyocardial infarctionpolyphenol

Substanzen

PolyphenolsMicroRNAsInterleukin-10

Autor:innen und Institutionen

  • Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, Department of Pediatric Dentistry, West China Second University Hospital, Sichuan University, Chengdu, 610041, China.
  • BMI Center for Biomass Materials and Nanointerfaces, National Engineering Laboratory for Clean Technology of Leather Manufacture, Ministry of Education Key Laboratory of Leather Chemistry and Engineering, College of Bio…
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60612, USA.
  • Department of Chemical and Biological Engineering, University of Colorado Boulder, Colorado, 80303, USA.
  • Department of Chemical and Biological Engineering, The University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.

ORCID-Profile: Junling Guo

Förderung

  • the Technology Project of Sichuan Province of China
  • State Key Laboratory of Polymer Materials Engineering
  • NIH HHS
  • the National Excellent Young Scientist Fund
  • National Natural Science Foundation of China
  • the Natural Science Foundation of Sichuan Province
  • the National Key R&D Program of China
  • the Sichuan Tianfu Emei Project

Zitieren

APA

Li, J., Gong, G., Zhang, Y., Zheng, Y., He, Y., Chen, M., He, X., Zheng, X., Gong, X., Liu, L., Zhou, K., Zhao, Z., Iv, C. W. S., Hua, Y., Li, Y., & Guo, J. (2025). Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation. Advanced Healthcare Materials, 14(2). https://doi.org/10.1002/adhm.202403595

Vancouver

Li J, Gong G, Zhang Y, Zheng Y, He Y, Chen M, et al. Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation. Advanced Healthcare Materials. 2025;14(2). doi:10.1002/adhm.202403595

BibTeX
@article{Li2025,
  author = {Li, Jiawen and Gong, Guidong and Zhang, Yue and Zheng, Yanjiang and He, Yunxiang and Chen, Mei and He, Xianglian and Zheng, Xiaolan and Gong, Xue and Liu, Lei and Zhou, Kaiyu and Zhao, Zongmin and Iv, C Wyatt Shields and Hua, Yimin and Li, Yifei and Guo, Junling},
  title = {Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  volume = {14},
  number = {2},
  doi = {10.1002/adhm.202403595}
}
Kostenlos starten →